Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | YAP1 | P46937 | 3/20 | 0.50 |
| ▸ | KLK7 | P49862 | 4/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158180 | 1.00 | BCL2 (0.53) | BCL2PTPN1YAP1KLK7KLK5 | |
| SCHEMBL13537887 | 1.00 | BCL2 (0.53) | BCL2PTPN1YAP1KLK7KLK5 | |
| SCHEMBL3291046 | 1.00 | BCL2 (0.53) | BCL2PTPN1YAP1KLK7KLK5 | |
| SCHEMBL8230963 | 1.00 | BCL2 (0.53) | BCL2PTPN1YAP1KLK7KLK5 | |
| SCHEMBL13617902 | 1.00 | BCL2 (0.53) | BCL2PTPN1YAP1KLK7KLK5 | |
| SCHEMBL5865405 | 0.90 | ATM (0.54) | KLK7KLK5PPARAATMPPARG | |
| SCHEMBL496136 | 0.90 | ATM (0.54) | KLK7KLK5PPARAATMPPARG | |
| SCHEMBL7438571 | 0.90 | ATM (0.54) | KLK7KLK5PPARAATMPPARG | |
| SCHEMBL639229 | 0.90 | ATM (0.54) | KLK7KLK5PPARAATMPPARG | |
| SCHEMBL2079109 | 0.90 | ATM (0.54) | KLK7KLK5PPARAATMPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212203-A1 | Antiviral Compounds | UNIVERSITY OF MASSACHUSETTS | 2023-07-06 | — | — | US | disclosed |
| US-11542288-B2 | Antiviral compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2023-01-03 | — | — | US | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1686113-B1 | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100305173-A1 | HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305173-A1 | HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES | STS, PRSS1, PRSS3 | BCL2 2537/4885PTPN1 2171/4885YAP1 4442/4885 |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | BCL2 3996/4885PTPN1 257/4885YAP1 2264/4885 |
| US-11542288-B2 | Antiviral compounds | ZC3HAV1, EIF2AK2, MAVS | BCL2 2925/4885PTPN1 4154/4885YAP1 4861/4885 |
| US-20230212203-A1 | Antiviral Compounds | ZC3HAV1, EIF2AK2, MAVS | BCL2 2925/4885PTPN1 4154/4885YAP1 4861/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | BCL2 4070/4885PTPN1 3330/4885YAP1 4420/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | BCL2 1781/4885PTPN1 1557/4885YAP1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.